Expression of PlGF splice variants was not correlated with clinical variables. Interestingly, expression levels of VEGFR-1 predict presence of DTCs in bone marrow (p = 0.002). Patients with DTC in ...

PlGF/VEGFR-1 signaling promotes macrophage polarization and accelerated tumor progression in obesity. Clinical Cancer Research, 2016; DOI: 10.1158/1078-0432.CCR-15-1839 ...

They also found that targeting the PlGF/VEGFR-1 interaction prevents weight gain in a genetically obese mouse model but worsens a diabetes-like condition, a worsening that was alleviated by use of ...

Similar to PlGF, its receptor, vascular endothelial growth factor receptor 1 (VEGFR-1, formerly termed Flt-1), was expressed at high levels in rheumatoid synovium and in PBMCs from patients with ...

In order to wisely skirt this catastrophic event, Lois E. H. Smith and colleagues utilized placental growth factor-1 (PlGF-1), which exclusively activates the VEGF receptor-1 (VEGFR-1).

1. Incio J, Tam J, Rahbari NN, et al. PlGF/VEGFR-1 signaling promotes macrophage polarization and accelerated tumor progression in obesity [published online February 9, 2016].

Their findings in cellular and animal models, as well as in patient tumor samples, indicate that targeting the PlGF/ VEGFR-1 pathway may be particularly effective in obese patients.

PLGF binds only to VEGFR-1, which is also present on the surface of leucocytes. Activation of these receptors by VEGF-A can result in neovascularization and vascular permeability.

We first confirmed that the serum levels of sFlt-1, free PlGF, and free VEGF were altered in women with clinical preeclampsia. 5,8 Among 23 pairs of women with preeclampsia and controls with ...

Cabozantinib is an oral, small-molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR) as well as MET and AXL, each of which has been implicated in the ...

More information: J. Incio et al. PlGF/VEGFR-1 signaling promotes macrophage polarization and accelerated tumor progression in obesity, Clinical Cancer Research (2016).